Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

The funding for 2 million people to receive the twice-yearly preventative treatment lenacapavir is ‘receding in the chaos’ of ...

It trades at 13.3 times forward earnings—below the industry average of 14, as measured by the NYSE Arca Pharmaceutical Index, ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events.

The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV ...

Lenacapavir works to both treat and prevent HIV, making it a promising drug should it be approved by the FDA later this month.

Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – – Also at CROI: New PURPOSE 1 Data Showcasing ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet – Phase 1 Data Indicate Potential for Use of Once ...